Cross-sensitivity of skin rashes with antiepileptic drug use

Neurology

Volumn 71, Issue 19, 2008, Pages 1527-1534

  Hirsch, L J ^a,c   Arif, H ^a   Nahm, E A ^a   Buchsbaum, R ^a   Resor, S R ^b   Bazil, C W ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS ALLERGY; EPILEPSY; FEMALE; FEVER; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HEPATITIS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN SENSITIVITY; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; MIDDLE AGED;

ADOLESCENT; ADULT; ANTICONVULSANTS; DRUG ERUPTIONS; EXANTHEMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 56149107740     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000334295.50403.4c     Document Type: Article

References (27)

1. Reunanen M, Dam M, Yuen AW. A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res 1996;23:149-155.
2. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-1709.
3. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 2007;48:1223-1244.
4. Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997;24:245-249.
5. Kahn HD, Faguet GB, Agee JF, Middleton HM, 3rd. Drug-induced liver injury: in vitro demonstration of hypersensitivity to both phenytoin and phenobarbital. Arch Intern Med 1984;144:1677-1679.
6. Misra UK, Kalita J, Rathore C. Phenytoin and carbamazepine cross reactivity: report of a case and review of literature. Postgrad Med J 2003;79:703-704.
7. Pelekanos J, Camfield P, Camfield C, Gordon K. Allergic rash due to antiepileptic drugs: clinical features and management. Epilepsia 1991;32:554-559.
8. Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991;32:741-749.
9. Reents SB, Luginbuhl WE, Davis SM. Phenytoin-carbamazepine cross-sensitivity. Dicp 1989;23:235-236.
10. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82:1826-1832.
11. Sierra NM, Garcia B, Marco J, et al. Cross hypersensitivity syndrome between phenytoin and carbamazepine. Pharm World Sci 2005;27:170-174.
12. Beran RG. Cross-reactive skin eruption with both carbamazepine and oxcarbazepine. Epilepsia 1993;34:163-165.
13. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
14. Chan HL, Tan KC. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol 1997;36:259.
15. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993;87:224-227.
16. Park BK, Naisbitt DJ, Gordon SF, Kitteringham NR, Pirmohamed M. Metabolic activation in drug allergies. Toxicology 2001;158:11-23.
17. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4 + , CD8 + , and CD4 + CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-981.
18. Hashizume H, Takigawa M, Tokura Y. Characterization of drug-specific T cells in phenobarbital-induced eruption. J Immunol 2002;168:5359-5368.
19. Mauri-Hellweg D, Bettens F, Mauri D, et al. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995;155:462-472.
20. Roujeau JC. Immune mechanisms in drug allergy. Allergol Int 2006;55:27-33.
21. Malik S, Arif H, Hirsch LJ. Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders. Exp Rev Neurother 2006;6: 1609-1627.
22. Maggs JL, Naisbitt DJ, Tettey JN, Pirmohamed M, Park BK. Metabolism of lamotrigine to a reactive arene oxide intermediate. Chem Res Toxicol 2000;13:1075-1081.
23. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia 2002;43 suppl 3:53-59.
24. Naisbitt DJ, Farrell J, Wong G, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003;111:1393-1403.
25. Romano A, Pettinato R, Andriolo M, et al. Hypersensitivity to aromatic anticonvulsants: in vivo and in vitro cross-reactivity studies. Curr Pharm Des 2006;12: 3373-3381.
26. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med 2003;349: 1628-1635.
27. Cleophas TJM, Zwinderman AH. Statistics applied to Clinical Trials. Springer; 2002.